Ftse Mib
34.660,38
-0,50%
DAX
18.557,27
-0,48%
S&P 500
5.346,99
-0,11%
NASDAQ
17.133,13
-0,23%
Bitcoin
69.192,42
-0,17%
Registration Strip Icon for default Registrati gratuitamente per ottenere quotazioni in tempo reale, grafici interattivi, flusso di opzioni in tempo reale e altro ancora.
Registrati

Quotazioni in diretta

Non abbiamo trovato risultati per:
Assicurati di aver scritto correttamente o prova ad allargare la ricerca.

Più Attivi

Toplist

Sembra che tu non sia connesso.
Clicca il pulsante qui sotto per accedere e visualizzare la tua cronologia recente.

Registrati

Sei già registrato? Accedi

Pepperstone

Inizia Ora

Pepperstone
Home Investire Azioni U.S.A. NASDAQ Immuneering Corporation (IMRX) Immuneering Corporation (IMRX) Notizie

IMRX

Immuneering (IMRX)

HOME News News di Agenzia

News di Agenzia

Da:
 Ti mostriamo gli articoli più rilevanti per la tua ricerca:NASDAQ:IMRX
DataOraFonteTitoloSimboloCompagnia
29/05/202422:05GlobeNewswire Inc.Immuneering to Present at the Jefferies Global Healthcare ConferenceNASDAQ:IMRXImmuneering Corporation
23/05/202422:20Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:IMRXImmuneering Corporation
23/05/202422:10Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:IMRXImmuneering Corporation
07/05/202422:05GlobeNewswire Inc.Immuneering Reports First Quarter 2024 Financial Results and Provides Business UpdatesNASDAQ:IMRXImmuneering Corporation
06/05/202422:30GlobeNewswire Inc.Immuneering Recognizes Melanoma Awareness MonthNASDAQ:IMRXImmuneering Corporation
09/04/202418:00GlobeNewswire Inc.IMM-1-104 is Synergistic with Chemotherapy in Pancreatic Cancer ModelsNASDAQ:IMRXImmuneering Corporation
03/04/202422:05GlobeNewswire Inc.Immuneering to Participate in the 23rd Annual Needham Virtual Healthcare ConferenceNASDAQ:IMRXImmuneering Corporation
27/03/202413:00GlobeNewswire Inc.Immuneering Announces First Patient Dosed in its Phase 1/2a Trial of IMM-6-415 to Treat Advanced Solid Tumors with RAF or RAS MutationsNASDAQ:IMRXImmuneering Corporation
14/03/202412:00GlobeNewswire Inc.Immuneering Announces Positive Topline Results from Phase 1 Portion of its Phase 1/2a Clinical Trial of IMM-1-104 in RAS-Mutant Solid TumorsNASDAQ:IMRXImmuneering Corporation
12/03/202413:00GlobeNewswire Inc.Immuneering Appoints Thomas J. Schall, Ph.D. to its Board of DirectorsNASDAQ:IMRXImmuneering Corporation
11/03/202413:00GlobeNewswire Inc.Immuneering Doses First Patient in Phase 2a Clinical Trial of IMM-1-104 in RAS-mutant Solid TumorsNASDAQ:IMRXImmuneering Corporation
05/03/202423:00GlobeNewswire Inc.Immuneering to Present Preclinical Data on Universal-RAS Program IMM-1-104 at American Association for Cancer Research Annual Meeting 2024NASDAQ:IMRXImmuneering Corporation
04/03/202414:00GlobeNewswire Inc.Immuneering to Participate in the Cowen 44th Annual Health Care ConferenceNASDAQ:IMRXImmuneering Corporation
01/03/202414:05Edgar (US Regulatory)Form 10-K - Annual report [Section 13 and 15(d), not S-K Item 405]NASDAQ:IMRXImmuneering Corporation
01/03/202414:00GlobeNewswire Inc.Immuneering Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Business UpdatesNASDAQ:IMRXImmuneering Corporation
20/02/202414:00GlobeNewswire Inc.Immuneering Receives FDA Fast Track Designation for IMM-1-104 in Pancreatic CancerNASDAQ:IMRXImmuneering Corporation
16/01/202422:37Edgar (US Regulatory)Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend]NASDAQ:IMRXImmuneering Corporation
12/12/202314:00GlobeNewswire Inc.Immuneering Announces FDA Clearance of IND Application for Phase 1/2a Trial of IMM-6-415 to Treat Advanced Solid Tumors with RAF or RAS MutationsNASDAQ:IMRXImmuneering Corporation
20/11/202322:05GlobeNewswire Inc.Immuneering to Present at the 35th Annual Piper Sandler Healthcare ConferenceNASDAQ:IMRXImmuneering Corporation
09/11/202322:12Edgar (US Regulatory)Form 10-Q - Quarterly report [Sections 13 or 15(d)]NASDAQ:IMRXImmuneering Corporation
09/11/202322:05GlobeNewswire Inc.Immuneering Reports Third Quarter 2023 Financial Results and Provides Business UpdatesNASDAQ:IMRXImmuneering Corporation
12/10/202322:05GlobeNewswire Inc.Immuneering Presents Preclinical Data Demonstrating Encouraging Anti-Tumor Activity for IMM-1-104 and IMM-6-415 at AACR-NCI-EORTC ConferenceNASDAQ:IMRXImmuneering Corporation
04/10/202322:05GlobeNewswire Inc.Immuneering to Present Preclinical Data on IMM-1-104 and IMM-6-415 at AACR-NCI-EORTC International Conference on Molecular Targets and Cancer TherapeuticsNASDAQ:IMRXImmuneering Corporation
06/09/202314:00GlobeNewswire Inc.Immuneering to Present at the Morgan Stanley Healthcare ConferenceNASDAQ:IMRXImmuneering Corporation
03/08/202322:05GlobeNewswire Inc.Immuneering Reports Second Quarter 2023 Financial Results and Provides Business UpdatesNASDAQ:IMRXImmuneering Corporation
15/06/202322:40Edgar (US Regulatory)Statement of Changes in Beneficial Ownership (4)NASDAQ:IMRXImmuneering Corporation
15/06/202322:17Edgar (US Regulatory)Current Report Filing (8-k)NASDAQ:IMRXImmuneering Corporation
05/06/202314:00GlobeNewswire Inc.Immuneering Completes Dose Escalation in the IMM-1-104 Phase 1 Clinical Trial for RAS-Mutant, Advanced Solid TumorsNASDAQ:IMRXImmuneering Corporation
30/05/202314:00GlobeNewswire Inc.Immuneering to Present at the Jefferies Healthcare ConferenceNASDAQ:IMRXImmuneering Corporation
05/05/202317:54Edgar (US Regulatory)Amended Statement of Ownership (sc 13g/a)NASDAQ:IMRXImmuneering Corporation
 Ti mostriamo gli articoli più rilevanti per la tua ricerca:NASDAQ:IMRX

La tua Cronologia

BIT
UCG
Unicredit
BIT
STMMI
ST Microelectronics
BIT
ISP
Intesa Sanpaolo
BIT
ENEL
Enel
BIT
STLAM
Stellantis NV
BIT
ENI
Eni
BIT
BMPS
Banca Monte Dei Paschi D...
BIT
RACE
Ferrari NV
BIT
BPE
Bper Banca
BIT
TRN
Terna Trasmissione Elett...
BIT
LDO
Leonardo
BIT
SRG
Snam
BIT
IVG
Iveco Group NV
BIT
CPR
Davide Campari
BIT
TEN
Tenaris
BIT
A2A
A2A
Delayed Upgrade Clock
Per accedere al tempo reale push di Borsa è necessario registrarsi.

Il sito ADVFN Italia è stato realizzato ed è gestito da PRODESFIN su licenza di ADVFN PLC.

PER CONTATTI E PUBBLICITA' SUL SITO CLICCARE QUI

Accedendo ai servizi offerti da ADVFN, ne si accettano le condizioni generali Termini & Condizioni

ADVFN Network